Introduction
Warts, hypogammaglobulinemia, infections, and myelokathexis (WHIM) syndrome is an autosomal dominant inheritance immune deficiency that in most kindreds is caused by a gain in function mutation (hyperactivity with failure to downregulate) in CXC chemokine receptor 4 (CXCR4). The commonly accepted name of the syndrome is an acronym derived from the four major features of the disorder [1] [2] [3] [4] [5] [6] . Myelokathexis of WHIM syndrome is characterized by myeloid hyperplasia with apoptosis of mature myeloid cells in the marrow. Most, but not all, patients with WHIM are heterozygous carriers of mutations of CXCR4 that cause partial truncations of the carboxyterminal segment of this receptor. When the CXCR4 mutation connection to WHIM was first identified in 2003, it was considered to be the first example of a human disease mediated by dysfunction of a chemokine receptor [7] . In the past 2 years, significant new information has been published about WHIM that provides an increased understanding of CXCR4 signaling. In addition, there have been recent reports about clinical problems in patients with WHIM that has added to our understanding of the clinical management of this disorder. These new findings of mechanisms and clinical features of WHIM will be reviewed.
A first step toward understanding the role of CXCR4 in WHIM requires description of structural features of this receptor. CXCR4 is a 352 amino acid member of the Gprotein-coupled receptor (GPCR) superfamily, with specificity for the chemokine CXCL12, also known as stromal cell-derived factor 1 (SDF1) [8] [9] [10] [11] . Mice genetically engineered to lack either SDF1 or CXCR4 have similar defects of B-cell lymphopoiesis, bone-marrow myelopoiesis, and cardiac septum formation that are associated with a late gestation lethal phenotype [12, 13] . Transcription of CXCR4 is regulated positively by nuclear respiratory factor-1 (NRF-1) and negatively by Ying Yang 1 (YY1) [14] [15] [16] . SDF1 binding to CXCR4 leads to activation of pathways that include G-protein-mediated and G-proteinindependent signaling [17] [18] [19] [20] [21] [22] . Understanding the regulation of expression and signaling pathways of SDF1 and of its cognate receptor, CXCR4, is likely to be an important area of additional discovery of clinical significance in the next few years. As one example of an area ripe for assessment, we do not know why patients with WHIM are particularly susceptible to infection with human papilloma virus (HPV), which in these patients not only causes warts, but also results in condyloma acuminata and dysplastic lesions of the genital-anal mucosa that often progresses to frank carcinoma. As SDF1 and CXCR4 are present in skin fibroblasts and keratinocytes, respectively, and may affect proliferation of keratinocytes, it is not far-fetched to speculate that HPV infection may impact regulation of expression or function of SDF1 and/or CXCR4 and that this balance is disturbed in WHIM to favor growth of HPV with proliferation and transformation of epithelium.
Specific mutations of CXCR4 identified in some families with myelokathexis include heterozygous mutations of R334X, S339fs342X, E343X, and G335X, all of which are located in and cause truncations of the intracellular carboxyterminus of CXCR4 [7, 23, 24] . However, as will be discussed in the section on Genetics, there may be other types of genetic lesions affecting CXCR4 signaling that can cause WHIM.
Clinical phenotype
The clinical features of 37 patients with WHIM have been reported [1, 3, 6, 7, 24, 25, 26 ,27 , [28] [29] [30] [31] [32] [33] [34] [35] [36] [37] [38] [39] . Pooling information from these diverse reports, the frequency of specific clinical features of WHIM at first presentation for warts, hypogammaglobulinemia, and neutropenia was 78.6 (22/28), 89.6 (26/29), and 91.7% (33/36) of patients, respectively. The clinical features that manifest in a particular patient and the age of initial diagnosis are variable. All patients from early childhood suffered from recurrent infections that include pneumonias, sinusitis, cellulitis, urinary tract infection, thrombophlebitis, omphalitis, osteomyelitis, deep soft tissue abscesses, and skin infections. Common pathogens include, but are not limited to, Haemophilus influenzae, Streptococcus pneumoniae, Klebsiella pneumoniae, Staphylococcus aureus, and Proteus mirabilis. Recurrent pneumonias may in some cases lead to severe bronchiectasis (Fig. 1) . Those patients who develop bronchiectasis may also suffer from chronic infection with Pseudomonas aeruginosa or Burkholderia cepacia. The immune deficiency in WHIM is manifested primarily by neutropenia, B-cell lymphopenia, and hypogammaglobulinemia. As expected, patients with WHIM have greater problem with bacterial infections (particularly with encapsulated organisms) than with virus infections. Patients with WHIM who are appropriately managed with granulocyte colony-stimulating factor (G-CSF) and periodic administration of intravenous gamma globulin (IVIG) appear to have little problem resolving infections with influenza, parainfluenza, herpes simplex, herpes zoster, and common respiratory viruses. However, there is likely a problem with control of Epstein-Barr virus (EBV), because there are two reports of patients with WHIM syndrome developing EBV-related lymphoproliferative disorders [33, 38] .
Patients with WHIM with warts characteristically have numerous warts on hands, feet, and trunk. They may also have genital and anal condyloma acuminata, and in female patients significant cervical and vulval dysplasia. Mucosal lesions often progress to frank carcinoma. All of these lesions are associated with HPV infection. The susceptibility to HPV and the resultant degree of lesion from this pathogen is very much out of proportion to the fact that there is not much increase in general susceptibility to virus infection in WHIM. Furthermore, the degree of HPVrelated disease in WHIM is even highly disproportionate to the level of problems with HPV seen in severe T-lymphocyte immunodeficiency disorders such as severe combined immune deficiency (SCID) in which there is a very significant increased susceptibility overall to infection with viruses. Thus, there appears to be a unique and specific failure of immune control of progression of HPV infection in WHIM. It is possible to speculate that the C-terminal truncating mutations of CXCR4 in WHIM, which enhance activity of the host CXCR4/SDF1 axis in skin and mucosa, may play a role in facilitating HPV infection that is detrimental to host defense.
Hematological findings
The bone marrow of patients with WHIM has a marked hyperplasia with many cells demonstrating characteristic
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Figure 1 Severe bronchiectasis in warts, hypogammaglobulinemia, infections, and myelokathexis syndrome This is a computerized axial tomography radiologic examination of the chest of an adult patient with warts, hypogammaglobulinemia, infections, and myelokathexis (WHIM) syndrome. This patient had frequent pneumonias and sinusitis since childhood, and demonstrates development of a significant degree of bilateral bronchiectasis.
abnormalities of cytoplasmic vacuolization, hypersegmented nuclei, and chromatin hypercondensation consistent with apoptosis [3] : a histologic pattern that in the older medical literature has been termed myelokathexis. Paradoxically, this increase in myeloid elements that includes an excessive number of apoptotic neutrophils in the bone marrow of patients with WHIM is associated with a very significant decrease in absolute counts of neutrophils in the peripheral blood. The clinical characteristics of the neutropenia observed in patients with WHIM differ from those in some other types of congenital neutropenia in that acute infection, stimulation with granulocyte-colony and granulocyte-monocyte-colony-stimulating factors (G-CSF, GM-CSF), epinephrine, or glucocorticoids induce a prompt release of neutrophils from the marrow that within hours may reach normal levels [32, 40] . This clinical observation together with the histological features of the bone marrow has suggested that the neutropenia might be a defect in marrow release of neutrophils rather than a production defect, though until recently definitive delineation of mechanism was lacking.
A very significant B-cell lymphopenia is a common finding and many patients may also manifest a decrease in number of T lymphocytes. However, the relative proportion of the main T-lymphocyte subsets appears normal, and in-vitro tests of T-lymphocyte proliferation to mitogens are normal [24, 34, 37] . B-lymphocyte counts in patients with WHIM are profoundly depressed with a particularly severe reduction in circulating CD27 þ memory B cells that affect both unswitched (IgD þ ) and switched (IgD À ) CD19 B lymphocytes [24] . The significant hypogammaglobulinemia most frequently involves IgG, but may also affect IgM. A likely clinical manifestation of this is the observed recurrent sinusitis, upper respiratory infections, and pneumonias with encapsulated bacteria and the development of significant bronchiectasis in a subset of patients (Fig. 1) . Patients are clearly helped by treatment with IVIG. However, patients with WHIM do have significant measurable responses to a clinically beneficial level to active immunizations indicating that the defect in humeral immunity is not complete [7, 24, 34] . More specifically, it has been reported that a patient with WHIM immunized with tetanustoxoid vaccine initially produced normal levels of specific antibody, but serum levels of antitetanus-toxoid immunoglobulin became undetectable after a year [24] . This suggests that patients with WHIM have normal capacity to produce specific antibody against antigens, but fail to maintain antibody production, which is manifested by a reduction in circulating CD27
þ memory B cells.
Diagnosis
The combination of recurrent bacterial infections and recalcitrant warts is a reliable sign of a primary immune 
Treatment and prognosis
The prognosis for patients with WHIM depends in part on early recognition of the disorder, with aggressive medical intervention to reduce the frequency of recurrent bacterial infections, and to detect and extirpate in the early stages any HPV lesions that appear to be dysplastic or malignant. Although both G-CSF and GM-CSF have been used to increase and maintain circulating neutrophil counts in the normal range, G-CSF is probably the preferred and best tolerated agent. The mechanism of action may in part involve, though likely is not limited to, elevating neutrophil counts in a positive autofeedback loop that involves enhanced release of neutrophil elastase [39, [41] [42] [43] . Neutrophil elastase cleaves SDF1 and CXCR4, thus reducing the activity of the SDF1/CXCR4 axis and thus enhancing release of mature neutrophils from the bone marrow to the peripheral blood [44, 45] . Dosing of G-CSF should be determined empirically for each patient, and even then adjustments may be needed periodically (in children as they grow; or in adults because of other factors). Reasonable initial dosage is human recombinant G-CSF at 3 mg per kg administered subcutaneously every other day, with a goal to adjust dosing to keep absolute neutrophil count in the circulation at or above 1500 per ml at the nadir of the alternate day.
With hypogammaglobulinemia, administration of IVIG is effective at decreasing risk of infections [1, 36] . Dosing may be every 6 weeks with a goal to achieve levels at or above the lower limit of the laboratory reference normal at nadir. It has been reported that the hypogammaglobulinemia may improve following treatment with G-CSF [32] . For that reason, it is important to periodically evaluate the nadir and adjust IVIG dosing. Use of prophylactic antibiotics in patients with WHIM has not been evaluated statistically, but it is not unreasonable to extrapolate from studies on other primary immune deficiencies, neutropenias or hypogammaglobulinemic states to support the use of antibiotic prophylaxis. A suggested regimen is daily trimethoprim-sulfamethoxazole to cover a broad range of encapsulated bacteria that includes pneumococcus and hemophilus together with antistaphylococcus activity. There is a risk, particularly in children, that in some individuals the trimethoprimsulfamethoxazole may adversely impact the neutropenia. Extended spectrum oral cephalosporin is an alternative.
Early aggressive diagnostic and therapeutic intervention for any suspected infection is essential. Pneumonias are common, and a subset of patients may develop significant bronchiectasis (Fig. 1) . Patients with extensive bronchiectasis benefit from advice and management by a pulmonary specialist because many of the interventions designed to manage patients with cystic fibrosis can be of benefit to these patients.
Mortality from infection in WHIM appears to be low in closely managed patients who are on G-CSF, IVIG, and prophylactic antibiotics, but lethal meningitis and septicemia have been reported. However, cancer is a significant cause of premature mortality in WHIM syndrome. The role of HPV and carcinoma will be discussed just below. Given the small number of reported cases of WHIM syndrome in the literature overall, it is highly significant that there are two cases of EBV B-cell lymphomas reported [33, 38] , of which one patient died from this lymphoproliferative disorder [38] .
Patients with WHIM with significant HPV lesions of mucosal and transitional areas of skin are at very significant risk of invasive destructive and eventually metastatic carcinomas. These HPV-related carcinomas are a significant cause of morbidity and premature mortality in WHIM. These lesions may be recurrent and extraordinary clinical vigilance is required with frequent assessment by a dermatologist and in female patients by a gynecologist. There must be a low threshold for biopsy of any suspect lesion with full surgical removal of any malignant or premalignant lesions. The availability of recombinant protein vaccines effective against those HPV serotypes responsible for causing mucosal cancers raises the question of whether early vaccination might help to reduce HPV-related malignancies in patients with WHIM. However, the B-cell defect in these patients may reduce the effectiveness or duration of protection and may require periodic reimmunization. This is an issue that should be studied in a prospective clinical protocol.
Genetics
The first report of the heterozygous carriage of a mutation in CXCR4 as the basis of autosomal dominant WHIM was reported in 2003 [7] . Since then results of sequencing have been reported for 26 patients with clinical features of WHIM (Table 1) [1, 3,6,7,24,25,26 ,27 ,28-39] , though in two of these patients no specific mutation was identified [25, 46 ] . One of these mutations R334X was found in 15 patients, the four other mutations being represented in only two to three each of the remaining patients. It is of note that all of the reported mutations in CXCR4 found in 24 patients with WHIM result in a premature stop codon that causes a truncation of the cytoplasmic Cterminus portion of the receptor. The C-terminal region of CXCR4 is known to contain canonical phosphorylation sites that by sequence homology are likely targets of Gprotein coupled receptor kinases (GPRKs) involved in ligand-induced GPCR endocytic internalization from the cell surface, a physiological negative feedback mechanism [47] . As will be discussed in greater detail below in the section on Biological Dysfunction, this type of lesion would be predicted to enhance and prolong the function of CXCR4 upon stimulation with SDF1, leading to a dominant gain of function affect as an explanation for the observed autosomal dominant inheritance.
Biological dysfunction
SDF binding to CXCR4 with SDF1 triggers a cascade of processes common to GPCRs [48] that include conformational change in the receptor [49] and the uncoupling from G-proteins that induces a host of downstream WHIM syndrome Kawai and Malech 23 effects. The uncoupling of G-proteins is associated with activation of the heterotrimeric Gabg-protein complex that mediates signal transduction and induces downstream cellular responses [50] . At the same time, negative feedback loops are activated, which include induction of GPRK and protein kinase C-mediated phosphorylation of the C-terminus cytoplasmic domain of CXCR4. This phosphorylation results in binding of b-arrestins to CXCR4 and interaction with C-terminal sequences, resulting in downregulation through endocytic internalization of receptor and desensitization to ligand stimulation [22, 51, 52] .
It is known that ligand blocking antibody to CXCR4 or the specific small molecule inhibitor of CXCR4, AMD3100, induces mobilization of neutrophils from bone marrow [53, 54] , suggesting that CXCR4 plays a role in retention of mature neutrophils in the marrow. It has been reported that both neutrophils and T lymphocytes from patients with WHIM who have C-terminal truncations of CXCR4 demonstrate enhanced chemotactic responses to SDF1 [24, 25, 55 ] . These findings raised the possibility that the enhanced function of WHIM mutant CXCR4 might be responsible for retention of otherwise mature neutrophils in the bone marrow beyond the time when they should be released into the circulation. Recently, this hypothesis was tested in a nonobese diabetic (NOD)/SCID mouse human hematopoietic stem cell xenograft model. In that study, normal human CD34 þ hematopoietic stem cells were forced to express the WHIM R334X mutant CXCR4 by gamma retrovirus mediated gene transfer and transplanted into the NOD/ SCID mouse. Neutrophils, arising from the R334X CXCR4 transduced human stem cells in the marrow of the NOD/SCID mice, demonstrated significantly decreased release from the xenograft marrow into the circulation compared with controls, and the WHIM R334X neutrophils retained in the marrow demonstrated increased rates of apoptosis [56 ] . However, when the normal human CD34 þ hematopoietic stem cells forced to express WHIM R334X mutant CXCR4 were instead differentiated in vitro into mature neutrophils in tissue culture, there was little enhancement of apoptosis compared with controls. These experiments show that the increased number of apoptotic mature myeloid cells in WHIM mostly is secondary to a failure of marrow release of neutrophils. The mature neutrophils in WHIM are instead retained in the marrow past their normal time of release, where they progress to senescence and apoptosis in that location rather than in the peripheral tissues or spleen as normally the case.
In related studies, when hematopoietic tissue culture cells or primary human CD34 þ cells were forced to express WHIM R334X mutant CXCR4 by gene transfer, the cells exhibited enhanced chemotactic and calcium efflux responses to SDF1 and defects in downregulationrelated internalization of receptor from the cell surface [57] . All of these findings are consistent with the well established role for the C-terminal cytoplasmic domain of GPCRs, including CXCR4, in regulating ligandmediated desensitization [58] and endocytic internalization/recycling of receptor [7, 24, 57] . Recent detailed biochemical studies suggest that C-terminal truncation of CXCR2 may actually result in enhanced binding of ß-arrestin to regions of the receptor other than the missing C-terminus, but that paradoxically in the absence of the usual additional interactions between ß-arrestin and the missing critical C-terminal regions, the result is prolonged activation of the receptor with failure to internalize receptor via endocytosis [55 ] .
Additional evidence connecting a decrease in ligandmediated downregulation of CXCR4 as a cause of WHIM comes from detailed studies of two unrelated patients with all of the characteristic clinical features of WHIM who lack detectable mutations in CXCR4 (Table 1) .
Cells from these patients demonstrate hyperactive responses to SDF1 [25, 46 ] . Furthermore, in cells from one of these two patients, there appeared to be a marked decrease in GRK3 protein and mRNA [25, 46 ] . Gene transfer-mediated expression of GRK3 in this patient's fibroblasts or leukocytes restored to normal levels the excessive chemotactic response and the ligand-mediated internalization of CXCR4 in response to SDF1. This demonstrates that the critical shared biochemical feature common to patients with WHIM with C-terminal truncating mutations of CXCR4 and to those patients with WHIM who lack detectable mutations in CXCR4 is the gain in function hyperactivity of CXCR4 in response to SDF1. This provides strong supportive evidence that WHIM may be broadly characterized as an immune deficiency disease of functional hyperactivity of CXCR4.
Conclusion
WHIM is an inherited immune deficiency characterized by neutropenia, B-cell lymphopenia, myelokathexis, hypogammaglobulinemia, recurrent infections, and a marked susceptibility to HPV infection with resultant warts, condyloma acuminata, and invasive mucosal carcinomas. There is emerging evidence that WHIM syndrome results from functional hyperactivity of CXCR4. The great majority of patients have a heterozygous gain in function C-terminus truncation mutation of CXCR4, though there may be patients manifesting WHIM due to alternate genetic causes of increased activity of CXCR4. The pathophysiologic mechanism by which increased activity of CXCR4 affects B-cell number and function is not known, nor is there yet an understanding of how this leads to enhanced susceptibility to HPV infection. Recent studies suggest that enhanced activity of CXCR4 on mature neutrophils in the bone marrow may prevent their release from the marrow, resulting in peripheral blood neutropenia. The normal progression to senescence of excess neutrophils retained in the marrow is likely responsible for the increased number of apoptotic neutrophils in the bone marrow observed histologically as myelokathexis. Current clinical management of WHIM includes treatment with G-CSF, IVIG, prophylactic antibiotics, and aggressive surveillance for and surgical extirpation of dysplastic skin and mucosal HPV-related lesions. Given that many of the clinical problems affecting WHIM may be a consequence of hyperfunction of CXCR4, we propose that systemic treatment of patients with WHIM with a potent inhibitor of CXCR4 function such as Mozobil (plerixafor; AMD3100), an agent in late stage clinical development by Genzyme Corporation, Cambridge, Massachusetts, United States, should be studied in an experimental clinical protocol.
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